Human medicines European public assessment report (EPAR): Gohibic, vilobelimab, Date of authorisation: 13/01/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Gohibic, vilobelimab, Date of authorisation: 13/01/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Kimmtrak, tebentafusp, Date of authorisation: 01/04/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Kimmtrak, tebentafusp, Date of authorisation: 01/04/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 69, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 69, Status: Authorised

Human medicines European public assessment report (EPAR): Levetiracetam Accord, levetiracetam, Date of authorisation: 03/10/2011, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Levetiracetam Accord, levetiracetam, Date of authorisation: 03/10/2011, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Dacogen, decitabine, Date of authorisation: 20/09/2012, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Dacogen, decitabine, Date of authorisation: 20/09/2012, Revision: 18, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.